Lafutidin

but-2-en-1-il)acetamid

Lafutidin

(IUPAC) ime
2-[(2-furilmetil)sulfinil]-N-((2Z)-4[4-(piperidin-1-ilmetil)piridin-2-il]oksi
Klinički podaci
Identifikatori
ATC kod	?
Hemijski podaci
Formula	?
Farmakoinformacioni podaci
Trudnoća	?
Pravni status

| image = Lafutidine.png | width = 250 | image2 = | width2 =

| tradename = | Drugs.com = Internacionalno ime leka | pregnancy_AU = | pregnancy_US = | pregnancy_category = | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = Oralno

| bioavailability = | protein_bound = | metabolism = | elimination_half-life = | excretion =

| CAS_number_Ref =  ^Y | CAS_number = 118288-08-7 | ATC_prefix = A02 | ATC_suffix = BA08 | ATC_supplemental = | PubChem = 5282136 | IUPHAR_ligand = | ChEMBL_Ref = | ChEMBL = | DrugBank_Ref = Šablon:Drugbankcite | DrugBank = | UNII_Ref =  ^Y | UNII = 49S4O7ADLC | KEGG_Ref =  ^Y | KEGG = D01131

| chemical_formula = | C=22 | H=29 | N=3 | O=4 | S=1 | molecular_weight = 431,54 g/mol | smiles = C1CCN(CC1)CC2=CC(=NC=C2)OCC=CCNC(=O)CS(=O)CC3=CC=CO3 | InChI = | InChIKey = | StdInChI_Ref =  ^Y | StdInChI = 1S/C22H29N3O4S/c26-21(18-30(27)17-20-7-6-14-28-20)23-9-2-5-13-29-22-15-19(8-10-24-22)16-25-11-3-1-4-12-25/h2,5-8,10,14-15H,1,3-4,9,11-13,16-18H2,(H,23,26)/b5-2- | StdInChIKey_Ref =  ^Y | StdInChIKey = KMZQAVXSMUKBPD-DJWKRKHSSA-N }}

Lafutidin (INN) je antagonist H₂ receptora.^[1][2]

Reference

1. Hardman JG, Limbird LE, Gilman AG. (2001). Goodman & Gilman's The Pharmacological Basis of Therapeutics (10 izd.). New York: McGraw-Hill. DOI:10.1036/0071422803. ISBN 0-07-135469-7.
2. Pdr Staff (2009). PDR: Physicians Desk Reference 2010 (Physicians' Desk Reference (Pdr)). Rozelle, N.S.W: Thomson Reuters. ISBN 1-56363-748-0.

Spoljašnje veze

	Portal Medicina
	Portal Hemija